Pipeline

June 18, 2018

Company	Drug/Device	Medical Condition	Status
Alnylam	lumasiran	Primary Hyperoxaluria Type 1 (PH1)	Phase I trial initiated enrolling 25 patients with PH1
Cynata Therapeutics	CYP-001	steroid-resistant acute graft-versus-host disease (GvHD)	Phase I trial initiated enrolling 8 patients with steroid-resistant acute GvHD
Vizuri Health Sciences	VZU00025	osteoarthritis	Phase II trial initiated
NeuroRx	NRX-101	suicidal bipolar depression	Phase IIb/III trial initiated enrolling 12 patients
Allergan	atogepant	episodic migraine pain	Phase IIb/III trial initiated enrolling 795 patients
icotec AG	BlackArmor Carbon/PEEK Interbody Cages	adults and children with hemophilia A without factor VIII inhibitors	510(k) Clearance granted by the FDA
Gold Standard Diagnostics	Borrelia burgdorferi IgG/IgM ELISA assay	Lyme disease bacteria	510(k) clearance granted by the FDA
AbbVie and Roche	Venclexta in combination with Rituxan (rituximab)	chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	Approval granted by the FDA
Genentech	Rituxan (rituximab)	moderate to severe pemphigus vulgaris (PV)	Approval granted by the FDA
Fujirebio Diagnostics	Lumipulse G B•R•A•H•M•S PCT Assay	bacterial infections	Clearance granted by the FDA
DyAnsys	Drug Relief	reduce the symptoms of opioid withdrawal without narcotics	Clearance granted by the FDA
Arcus Biosciences	AB928	breast and gynecologic malignancies	Clearance granted by the FDA
Nordic Nanovector	Betalutin	relapsed or refractory follicular lymphoma (FL)	Fast Track Designation granted by the FDA
Ironwood Pharma	olinciguat (IW-1701)	sickle cell disease	Orphan Drug Designation granted by the FDA
AMO Pharma	AMO-04	Rett Syndrome	Orphan Drug Designation granted by the FDA
Samus Therapeutics	PU-H71	myelofibrosis	Orphan Drug Designation granted by the FDA